Infectomycin Saft

Erythromycin estolate, the active ingredient in Infectomycin Saft, is a macrolide antibiotic presented as an oral syrup for systemic use. It treats a range of bacterial infections in children and adults, including respiratory and skin infections. It is formulated for easy administration and is suitable for patients who require a liquid dosage form.

GNH USA supplies Infectomycin Saft as a licensed, GDP‑compliant international pharmaceutical supplier, ensuring quality and regulatory compliance while serving hospitals, pharmacies and clinics worldwide, and supports timely therapeutic access across regions.

Erythromycin estolate is used to treat bacterial infections affecting various organ systems.

- Respiratory tract infections: clears community‑acquired pneumonia, bronchitis and sinusitis caused by susceptible bacteria. - Skin and soft‑tissue infections: treats cellulitis, impetigo and wound infections. - Otitis media: effective against middle‑ear infections in children. - Sexually transmitted infections: used for uncomplicated chlamydial infections.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: rash, angioedema or anaphylaxis.

Precautions should be taken to minimise adverse outcomes and ensure safe use.

- Assess liver function: monitor hepatic enzymes before and during therapy. - Monitor cardiac rhythm: avoid in patients with known QT prolongation. - Avoid in patients with known hypersensitivity to macrolides. - Use with caution in renal impairment: dose adjustment may be required. - Consider drug interactions: review concomitant medications for CYP3A4 substrates. - Store at ambient temperature: keep in original container, protect from moisture and light.

Erythromycin estolate can interact with several medicines; awareness helps prevent toxicity.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may increase erythromycin levels and toxicity. - Ergot alkaloids: risk of ergotism due to increased ergot exposure. - Theophylline: elevated plasma concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Statins (especially simvastatin): increased risk of myopathy. - Carbamazepine: may reduce erythromycin efficacy by inducing metabolism.